Share ownership Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:33:28 06/03/2026 am IST			5-day change	1st Jan Change
237.50 ^USD	-3.18%		-2.56%	+14.64%

01:29am	Johnson & Johnson's Janssen Biotech Unit Secures US FDA Approval for Multiple Myeloma Treatment	MT
12:50am	US FDA approves JNJ's blood cancer drug	RE

Share class: Johnson & Johnson

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,12,05,37,693	2,40,54,17,695 ( 77.08 %)	71,29,21,000 ( 22.85 %)	77.08 %

Major shareholders: Johnson & Johnson

Name	Equities	%	Valuation
The Vanguard Group, Inc. 10.1 %	24,34,55,135	10.1 %	55 325 M $
Vanguard Fiduciary Trust Co. 9.976 %	24,03,49,660	9.976 %	54 619 M $
BlackRock Advisors LLC 6.475 %	15,60,07,213	6.475 %	35 453 M $
STATE STREET CORPORATION 5.556 %	13,38,69,843	5.556 %	30 422 M $
JPMorgan Investment Management, Inc. 2.434 %	5,86,39,437	2.434 %	13 326 M $
Geode Capital Management LLC 2.405 %	5,79,53,747	2.405 %	13 170 M $
BlackRock Life Ltd. 1.975 %	4,75,89,849	1.975 %	10 815 M $
Eaton Vance Management 1.923 %	4,63,25,589	1.923 %	10 527 M $
Norges Bank (13F) 1.389 %	3,34,59,884	1.389 %	7 604 M $
State Farm Investment Management Corp. 1.311 %	3,15,90,952	1.311 %	7 179 M $
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Itaú Unibanco Asset Management Ltda. 0.000498 %	1,80,007	0.000498 %	3 M $
Morgan Stanley Administradora de Carteiras SA 0 %	51	0 %	776 $

Breakdown by shareholder type

Institutional	68.07%
Other	7.98%
State Street Corp.	5.56%
Schweizerische Nationalbank	0.27%
Sumitomo Mitsui Trust Group, Inc.	0.25%
Manulife Financial Corp.	0.16%
Governments	0.15%
Swedbank AB	0.1%
Danske Bank A/S	0.09%
SEI Investments Co.	0.08%
The Bank of Nova Scotia	0.05%
Fifth Third Bancorp	0.05%
Skandinaviska Enskilda Banken AB	0.05%
Regions Financial Corp.	0.04%
Commerzbank AG	0.04%
Zurich Insurance Group AG	0.04%
Individuals	0.04%
Markel Group, Inc.	0.03%
First Financial Bankshares, Inc.	0.03%
Rathbones Group Plc	0.03%
Silvercrest Asset Management Group, Inc.	0.02%
Peapack-Gladstone Financial Corp.	0.02%
ING Groep NV	0.02%
Hikari Tsushin, Inc.	0.01%
First Horizon Corp. (Tennessee)	0.01%
Associated Banc-Corp	0.01%
The Allstate Corp.	0.01%
Cincinnati Financial Corp.	0.01%
Hancock Whitney Corp.	0.01%
Cullen/Frost Bankers, Inc.	0.01%
Old Republic International Corp.	0.01%
Unknown	16.75%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	64.29%
United Kingdom	7.65%
Canada	3.4%
Norway	1.48%
Australia	0.85%
France	0.83%
Japan	0.77%
Switzerland	0.63%
Sweden	0.59%
Germany	0.56%
Denmark	0.44%
Hong Kong	0.41%
South Korea	0.29%
Netherlands	0.15%
Ireland	0.15%
Luxembourg	0.13%
Italy	0.13%
Belgium	0.12%
Finland	0.06%
New Zealand	0.05%
Singapore	0.04%
Individuals	0.04%
Spain	0.03%
Austria	0.03%
Czech Republic	0.03%
Liechtenstein	0.02%
Portugal	0.02%
South Africa	0.02%
Brazil	0.01%
Saudi Arabia	0.01%
China	0.01%
Slovenia	0.01%

Based on 1000 largest holdings

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2025, Johnson & Johnson has 63 manufacturing facilities located in the United States (22), North America (7), Europe (22), Africa and Asia/Pacific (12). The United States accounts for 57.1% of net sales.

Employees

1,38,200

Sector

Pharmaceuticals

Calendar

14/04 - Earnings release - Q1 2026

More about the company